, Volume 71, Issue 7, pp 827–840 | Cite as

Obsessive-Compulsive Disorder, Impulse Control Disorders and Drug Addiction

Common Features and Potential Treatments
  • Leonardo F. Fontenelle
  • Sanne Oostermeijer
  • Ben J. Harrison
  • Christos Pantelis
  • Murat Yücel
Current Opinion


The basic concepts underlying compulsive, impulsive and addictive behaviours overlap, which may help explain why laymen use these expressions interchangeably. Although there has been a large research effort to better characterize and disentangle these behaviours, clinicians and scientists are still unable to clearly differentiate them. Accordingly, obsessive-compulsive disorder (OCD), impulse control disorders (ICD) and substance-related disorders (SUD) overlap on different levels, including phenomenology, co-morbidity, neurocircuitry, neurocognition, neurochemistry and family history. In this review we summarize these issues with particular emphasis on the role of the opioid system in the pathophysiology and treatment of OCD, ICD and SUD. We postulate that with progression and chronicity of OCD, the proportion of the OCD-related behaviours (e.g. checking, washing, ordering and hoarding, among others) that are driven by impulsive ‘rash’ processes increase as involvement of more ventral striatal circuits becomes prominent. In contrast, as SUD and ICD progress, the proportion of the SUD- and ICD-related behaviours that are driven by compulsive ‘habitual’ processes increase as involvement of more dorsal striatal circuits become prominent. We are not arguing that, with time, ICD becomes OCD or vice versa. Instead, we are proposing that these disorders may acquire qualities of the other with time. In other words, while patients with ICD/SUD may develop ‘compulsive impulsions’, patients with OCD may exhibit ‘impulsive compulsions’. There are many potential implications of our model. Theoretically, OCD patients exhibiting impulsive or addictive features could be managed with drugs that address the quality of the underlying drives and the involvement of neural systems. For example, agents for the reduction or prevention of relapse of addiction (e.g. heavy drinking), which modulate the cortico-mesolimbic dopamine system through the opioid (e.g. buprenorphine and naltrexone), glutamate (e.g. topiramate), serotonin (e.g. ondansetron) or g-aminobutyric acid (e.g. baclofen and topiramate) systems, may prove to show some benefit in certain forms of OCD. Based on the available evidence, we suggest that the treatment of patients with these disorders must account for alterations in the underlying motivations and neurobiology of the condition. We provide an initial guide to the specific treatments that future clinical trials might consider in patients with OCD. For example, it might be wise to test naltrexone in patients with co-morbid SUD and ICD, topiramate in patients with co-morbid ICD and eating disorders, and baclofen in patients with co-morbid Tourette's syndrome. These trials could also include scales aimed at assessing underlying impulsivity (e.g. Barratt Impulsiveness Scale) to check whether this construct might predict response to drugs acting on the reward system.


Deep Brain Stimulation Topiramate Naltrexone Baclofen Pathological Gambling 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    John CE, McCracken CB, Haber SN. Motivation on the Mediterranean: reward, compulsions and habit formation. Neurosci Biobehav Rev 2010 Jan; 34(1): 2–6PubMedCrossRefGoogle Scholar
  2. 2.
    Fineberg NA, Potenza MN, Chamberlain SR, et al. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neurops chopharmacology 2010 Feb; 35(3): 591–604CrossRefGoogle Scholar
  3. 3.
    Rasmussen SA, Eisen JL. Clinical and epidemiologic findings of significance to neuropharmacologic trials in OCD. Psychopharmacol Bull 1988; 24(3): 466–70PubMedGoogle Scholar
  4. 4.
    Ferrao YA, Miguel E, Stein DJ. Tourette's syndrome, trichotillomania, and obsessive-compulsive disorder: how closely are they related? Psychiatry Res 2009 Nov 30; 170(1): 32–42PubMedCrossRefGoogle Scholar
  5. 5.
    Völlstadt-Klein S, Wichert S, Rabinstein J, et al. Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum. Addiction 2010 Oct; 105(10): 1741–9PubMedCrossRefGoogle Scholar
  6. 6.
    Eisen JL, Rasmussen SA. Coexisting obsessive compulsive disorder and alcoholism. J Clin Psychiatry 1989 Mar; 50(3): 96–8PubMedGoogle Scholar
  7. 7.
    Friedman I, Dar R, Shilony E. Compulsivity and obses-sionality in opioid addiction. J Nerv Ment Dis 2000 Mar; 188(3): 155–62PubMedCrossRefGoogle Scholar
  8. 8.
    Mancebo MC, Grant JE, Pinto A, et al. Substance use disorders in an obsessive compulsive disorder clinical sample. J Anxiety Disord 2009 May; 23(4): 429–35PubMedCrossRefGoogle Scholar
  9. 9.
    Grant JE, Mancebo MC, Pinto A, et al. Impulse control disorders in adults with obsessive compulsive disorder. J Psychiatr Res 2006 Sep; 40(6): 494–501PubMedCrossRefGoogle Scholar
  10. 10.
    Fontenelle LF, Mendlowicz MV, Versiani M. Impulse control disorders in patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci 2005 Feb; 59(1): 30–7PubMedCrossRefGoogle Scholar
  11. 11.
    Kühn S, Gallinat J. Common biology of craving across legal and illegal drugs: a quantitative meta-analysis of cuereactivity brain response. Eur J Neurosci 2011 Apr;33(7): 1318–26PubMedCrossRefGoogle Scholar
  12. 12.
    McGuire PK, Bench CJ, Frith CD, et al. Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry 1994 Apr; 164(4): 459–68PubMedCrossRefGoogle Scholar
  13. 13.
    Rauch SL, Jenike MA, Alpert NM, et al. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 1994 Jan; 51(1): 62–70PubMedCrossRefGoogle Scholar
  14. 14.
    Breiter HC, Rauch SL, Kwong KK, et al. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry 1996 Jul;53(7): 595–606PubMedCrossRefGoogle Scholar
  15. 15.
    Mataix-Cols D, Wooderson S, Lawrence N, et al. Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder. Arch Gen Psychiatry 2004 Jun; 61(6): 564–76PubMedCrossRefGoogle Scholar
  16. 16.
    Schienle A, Schafer A, Stark R, et al. Neural responses of OCD patients towards disorder-relevant, generally disgust-inducing and fear-inducing pictures. Int J Psychophysiol 2005 Jul; 57(1): 69–77PubMedCrossRefGoogle Scholar
  17. 17.
    Rauch SL, Shin LM, Dougherty DD, et al. Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 2002 Nov; 27(5): 782–91PubMedCrossRefGoogle Scholar
  18. 18.
    Kober H, Mende-Siedlecki P, Kross EF, et al. Prefrontalstriatal pathway underlies cognitive regulation of craving. Proc Natl Acad Sci USA 2010 Aug 17; 107(33): 14811–6PubMedCrossRefGoogle Scholar
  19. 19.
    Nakao T, Nakagawa A, Yoshiura T, et al. Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biol Psychiatry 2005 Apr 15; 57(8): 901–10PubMedCrossRefGoogle Scholar
  20. 20.
    Rotge JY, Guehl D, Dilharreguy B, et al. Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci 2008 Sep; 33(5): 405–12PubMedGoogle Scholar
  21. 21.
    Chamberlain SR, Menzies L, Hampshire A, et al. Orbito-frontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science 2008 Jul 18; 321(5887): 421–2PubMedCrossRefGoogle Scholar
  22. 22.
    Freyer T, Kloppel S, Tuscher O, et al. Frontostriatal activation in patients with obsessive-compulsive disorder before and after cognitive behavioral therapy. Psychol Med 2011 Jan; 41(1): 207–16PubMedCrossRefGoogle Scholar
  23. 23.
    de Ruiter MB, Veltman DJ, Goudriaan AE, et al. Response perseveration and ventral prefrontal sensitivity to reward and punishment in male problem gamblers and smokers. Neuropsychopharmacology 2009 Mar; 34(4): 1027–38PubMedCrossRefGoogle Scholar
  24. 24.
    Page LA, Rubia K, Deeley Q, et al. A functional magnetic resonance imaging study of inhibitory control in obsessive-compulsive disorder. Psychiatry Res 2009 Dec 30; 174(3): 202–9PubMedCrossRefGoogle Scholar
  25. 25.
    Yucel M, Lubman DI. Neurocognitive and neuroimaging evidence of behavioural dysregulation in human drug addiction: implications for diagnosis, treatment and prevention. Drug Alcohol Rev 2007 Jan; 26(1): 33–9PubMedCrossRefGoogle Scholar
  26. 26.
    Yucel M, Lubman DI, Solowij N, et al. Understanding drug addiction: a neuropsychological perspective. Aust N Z J Psychiatry 2007 Dec; 41(12): 957–68PubMedCrossRefGoogle Scholar
  27. 27.
    Feil J, Sheppard D, Fitzgerald PB, et al. Addiction, compulsive drug seeking, and the role of frontostriatal mechanisms in regulating inhibitory control. Neurosci Biobehav Rev 2010 Nov; 35(2): 248–75PubMedCrossRefGoogle Scholar
  28. 28.
    Hester R, Lubman DI, Yucel M. The role of executive control in human drug addiction. Curr Top Behav Neurosci 2010; 3: 301–18PubMedCrossRefGoogle Scholar
  29. 29.
    Potenza MN, Steinberg MA, Skudlarski P, et al. Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry 2003 Aug; 60(8): 828–36PubMedCrossRefGoogle Scholar
  30. 30.
    Dannon PN, Kushnir T, Aizer A, et al. Alternation learning in pathological gamblers: an fMRI Study. Brain Imaging Behav 2011 Mar; 5(1): 45–51PubMedCrossRefGoogle Scholar
  31. 31.
    Coccaro EF, McCloskey MS, Fitzgerald DA, et al. Amygdala and orbitofrontal reactivity to social threat in individuals with impulsive aggression. Biol Psychiatry 2007 Jul 15; 62(2): 168–78PubMedCrossRefGoogle Scholar
  32. 32.
    Reuter J, Raedler T, Rose M, et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005 Feb; 8(2): 147–8PubMedCrossRefGoogle Scholar
  33. 33.
    Goldstein RZ, Tomasi D, Alia-Klein N, et al. Subjective sensitivity to monetary gradients is associated with frontolimbic activation to reward in cocaine abusers. Drug Alcohol Depend 2007 Mar 16; 87(2-3): 233–40PubMedCrossRefGoogle Scholar
  34. 34.
    Figee M, Vink M, de Geus F, et al. Dysfunctional reward circuitry in obsessive-compulsive disorder [abstract]. European Neuropsychopharmacology 2010; 20 Suppl. 3: S302CrossRefGoogle Scholar
  35. 35.
    Muller UJ, Sturm V, Voges J, et al. Successful treatment of chronic resistant alcoholism by deep brain stimulation of nucleus accumbens: first experience with three cases. Pharmacopsychiatry 2009 Nov; 42(6): 288–91PubMedCrossRefGoogle Scholar
  36. 36.
    Mantione M, van de Brink W, Schuurman PR, et al. Smoking cessation and weight loss after chronic deep brain stimulation of the nucleus accumbens: therapeutic and research implications: case report. Neurosurgery 2010 Jan; 66(1): E218; discussion E218PubMedCrossRefGoogle Scholar
  37. 37.
    Harrison BJ, Soriano-Mas C, Pujol J, et al. Altered corticostriatal functional connectivity in obsessive-compulsive disorder. Arch Gen Psychiatry 2009 Nov; 66(11): 1189–200PubMedCrossRefGoogle Scholar
  38. 38.
    Ma N, Liu Y, Li N, et al. Addiction related alteration in resting-state brain connectivity. Neuroimage 2010 Jan 1; 49(1): 738–44PubMedCrossRefGoogle Scholar
  39. 39.
    Baxter Jr LR, Phelps ME, Mazziotta JC, et al. Local cerebral glucose metabolic rates in obsessive-compulsive disorder: a comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 1987 Mar; 44(3): 211–8PubMedCrossRefGoogle Scholar
  40. 40.
    Baxter Jr LR, Schwartz JM, Mazziotta JC, et al. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry 1988 Dec; 145(12): 1560–3PubMedGoogle Scholar
  41. 41.
    Nordahl TE, Benkelfat C, Semple WE, et al. Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology 1989 Mar; 2(1): 23–8PubMedCrossRefGoogle Scholar
  42. 42.
    Perani D, Colombo C, Bressi S, et al. [18F]FDG PET study in obsessive-compulsive disorder: a clinical/metabolic correlation study after treatment. Br J Psychiatry 1995 Feb; 166(2): 244–50PubMedCrossRefGoogle Scholar
  43. 43.
    Kwon JS, Kim JJ, Lee DW, et al. Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive-compulsive disorder. Psychiatry Res 2003 Jan 20; 122(1): 37–47PubMedCrossRefGoogle Scholar
  44. 44.
    Pallanti S, Haznedar MM, Hollander E, et al. Basal ganglia activity in pathological gambling: a fluorodeoxyglucose-positron emission tomography study. Neuropsychobiology 2010;62(2): 132–8PubMedCrossRefGoogle Scholar
  45. 45.
    Schiffer WK, Lee DE, Brodie JD, et al. Imaging addiction with PET: is insight in sight? Drug Discov Today 2005 Apr 15; 10(8): 547–62PubMedCrossRefGoogle Scholar
  46. 46.
    van den Heuvel OA, van der Werf YD, Verhoef KM, et al. Frontal-striatal abnormalities underlying behaviours in the compulsive-impulsive spectrum. J Neurol Sci 2010 Feb 15; 289(1-2): 55–9PubMedCrossRefGoogle Scholar
  47. 47.
    Bechara A, Tranel D, Damasio H, et al. Failure to respond autonomically to anticipated future outcomes following damage to prefrontal cortex. Cereb Cortex 1996 Mar–Apr; 6(2): 215–25PubMedCrossRefGoogle Scholar
  48. 48.
    Barbey AK, Koenigs M, Grafman J. Orbitofrontal contributions to human working memory. Cereb Cortex 2010 Apr; 21(4): 789–95PubMedCrossRefGoogle Scholar
  49. 49.
    Aron AR, Fletcher PC, Bullmore ET, et al. Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat Neurosci 2003 Feb; 6(2): 115–6PubMedCrossRefGoogle Scholar
  50. 50.
    Owen AM, Downes JJ, Sahakian BJ, et al. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 1990; 28(10): 1021–34PubMedCrossRefGoogle Scholar
  51. 51.
    Frey S, Petrides M. Orbitofrontal cortex: a key prefrontal region for encoding information. Proc Natl Acad Sci U S A 2000 Jul 18; 97(15): 8723–7PubMedCrossRefGoogle Scholar
  52. 52.
    Clarke HF, Dalley JW, Crofts HS, et al. Cognitive inflexibility after prefrontal serotonin depletion. Science 2004 May 7; 304(5672): 878–80PubMedCrossRefGoogle Scholar
  53. 53.
    Cavedini P, Gorini A, Bellodi L. Understanding obsessive-compulsive disorder: focus on decision making. Neuropsychol Rev 2006 Mar; 16(1): 3–15PubMedCrossRefGoogle Scholar
  54. 54.
    Papageorgiou C, Rabavilas A, Liappas I, et al. Do obsessive-compulsive patients and abstinent heroin addicts share a common psychophysiological mechanism? Neuropsychobiology 2003; 47(1): 1–11PubMedCrossRefGoogle Scholar
  55. 55.
    Chamberlain SR, Fineberg NA, Blackwell AD, et al. Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. Am J Psychiatry 2006 Jul; 163(7): 1282–4PubMedCrossRefGoogle Scholar
  56. 56.
    Chamberlain SR, Fineberg NA, Menzies LA, et al. Impaired cognitive flexibility and motor inhibition in unaffected first-degree relatives of patients with obsessive-compulsive disorder. Am J Psychiatry 2007 Feb; 164(2): 335–8PubMedCrossRefGoogle Scholar
  57. 57.
    Chamberlain SR, Fineberg NA, Blackwell AD, et al. A neuropsychological comparison of obsessive-compulsive disorder and trichotillomania. Neuropsychologia 2007 Mar 2; 45(4): 654–62PubMedCrossRefGoogle Scholar
  58. 58.
    Chamberlain SR, Blackwell AD, Fineberg NA, et al. Strategy implementation in obsessive-compulsive disorder and trichotillomania. Psychol Med 2006 Jan; 36(1): 91–7PubMedCrossRefGoogle Scholar
  59. 59.
    Westenberg HG, Fineberg NA, Denys D. Neurobiology of obsessive-compulsive disorder: serotonin and beyond. CNS Spectr 2007 Feb; 12 (2 Suppl. 3): 14–27PubMedGoogle Scholar
  60. 60.
    Carlsson ML. On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001 Jan; 25(1): 5–26PubMedCrossRefGoogle Scholar
  61. 61.
    McDougle CJ, Barr LC, Goodman WK, et al. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 1999 Jan; 24(1): 1–24PubMedCrossRefGoogle Scholar
  62. 62.
    Roy BF, Benkelfat C, Hill JL, et al. Serum antibody for somatostatin-14 and prodynorphin 209–240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis, and advanced HIV infection. Biol Psychiatry 1994 Mar 1; 35(5): 335–44PubMedCrossRefGoogle Scholar
  63. 63.
    Weizman R, Gil-Ad I, Hermesh H, et al. Immunoreactive beta-endorphin, cortisol, and growth hormone plasma levels in obsessive-compulsive disorder. Clin Neuro-pharmacol 1990 Aug; 13(4): 297–302Google Scholar
  64. 64.
    Leckman JF, Riddle MA, Berrettini WH, et al. Elevated CSF dynorphin A [1-8] in Tourette's syndrome. Life Sci 1988; 43(24): 2015–23PubMedCrossRefGoogle Scholar
  65. 65.
    Nurnberg HG, Keith SJ, Paxton DM. Consideration of the relevance of ethological animal models for human repetitive behavioral spectrum disorders. Biol Psychiatry 1997 Jan 15; 41(2): 226–9PubMedCrossRefGoogle Scholar
  66. 66.
    Nestadt G, Samuels J, Riddle M, et al. A family study of obsessive-compulsive disorder. Arch Gen Psychiatry 2000 Apr; 57(4): 358–63PubMedCrossRefGoogle Scholar
  67. 67.
    Hanna GL, Fischer DJ, Chadha KR, et al. Familial and sporadic subtypes of early-onset obsessive-compulsive disorder. Biol Psychiatry 2005 Apr 15; 57(8): 895–900PubMedCrossRefGoogle Scholar
  68. 68.
    Mangold DL, Peyrot M, Giggey P, et al. Endogenous opioid activity is associated with obsessive-compulsive symptomology in individuals with a family history of alcoholism. Neuropsychopharmacology 2000 Jun; 22(6): 595–607PubMedCrossRefGoogle Scholar
  69. 69.
    Hess CW, Raymond D, Aguiar Pde C, et al. Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology 2007 Feb 13; 68(7): 522–4PubMedCrossRefGoogle Scholar
  70. 70.
    Urraca N, Camarena B, Gomez-Caudillo L, et al. Mu opioid receptor gene as a candidate for the study of obsessive compulsive disorder with and without tics. Am J Med Genet B Neuropsychiatr Genet 2004 May 15; 127B(1): 94–6PubMedCrossRefGoogle Scholar
  71. 71.
    Hollander E, Wong CM. Obsessive-compulsive spectrum disorders. J Clin Psychiatry 1995; 56 Suppl. 4: 3–6; discussion 53–5PubMedGoogle Scholar
  72. 72.
    Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010 Jan; 35(1): 217–38PubMedCrossRefGoogle Scholar
  73. 73.
    Belin D, Mar AC, Dalley JW, et al. High impulsivity predicts the switch to compulsive cocaine-taking. Science 2008 Jun 6; 320(5881): 1352–5PubMedCrossRefGoogle Scholar
  74. 74.
    Everitt BJ, Belin D, Economidou D, et al. Review: neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos Trans R Soc Lond B Biol Sci 2008 Oct 12; 363(1507): 3125–35PubMedCrossRefGoogle Scholar
  75. 75.
    Endrass T, Kloft L, Kaufmann C, et al. Approach and avoidance learning in obsessive-compulsive disorder. Depress Anxiety 2011 Feb; 28(2): 166–72PubMedCrossRefGoogle Scholar
  76. 76.
    Greenberg BD, Gabriels LA, Malone Jr DA, et al. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry 2010 Jan; 15(1): 64–79PubMedCrossRefGoogle Scholar
  77. 77.
    Johnson BA. Medication treatment of different types of alcoholism. Am J Psychiatry 2010 Jun; 167(6): 630–9PubMedCrossRefGoogle Scholar
  78. 78.
    Fontenelle LF, Nascimento AL, Mendlowicz MV, et al. An update on the pharmacological treatment of obsessive-compulsive disorder. Expert Opin Pharmacother 2007 Apr; 8(5): 563–83PubMedCrossRefGoogle Scholar
  79. 79.
    Hantouche EG, Demonfaucon C. Resistant obsessive compulsive disorder (ROC): clinical picture, predictive factors and influence of affective temperaments [in French]. Encephale 2008 Dec; 34(6): 611–7PubMedCrossRefGoogle Scholar
  80. 80.
    Dell'Osso B, Hollander E. The impact of comorbidity on the management of pathological gambling. CNS Spectr 2005 Aug; 10(8): 619–21PubMedGoogle Scholar
  81. 81.
    Rojas-Corrales MO, Gibert-Rahola J, Mico JA. Role of atypical opiates in OCD: experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior. Psychopharmacology (Berl) 2007 Feb; 190(2): 221–31CrossRefGoogle Scholar
  82. 82.
    Insel TR, Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry 1983 Sep; 140(9): 1219–20PubMedGoogle Scholar
  83. 83.
    Keuler DJ, Altemus M, Michelson D, et al. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol Psychiatry 1996 Jul 15; 40(2): 154–6PubMedCrossRefGoogle Scholar
  84. 84.
    Goldsmith TB, Shapira NA, Keck Jr PE. Rapid remission of OCD with tramadol hydrochloride. Am J Psychiatry 1999 Apr; 156(4): 660–1PubMedGoogle Scholar
  85. 85.
    Shapira NA, Keck Jr PE, Goldsmith TD, et al. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety 1997; 6(4): 170–3PubMedCrossRefGoogle Scholar
  86. 86.
    Koran LM, Aboujaoude E, Bullock KD, et al. Doubleblind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2005 Mar; 66(3): 353–9PubMedCrossRefGoogle Scholar
  87. 87.
    Khazaal Y, Krenz S, Benmebarek M, et al. Worsening of obsessive-compulsive symptoms under methadone tapering. Prog Neuropsychopharmacol Biol Psychiatry 2006 Sep 30; 30(7): 1350–2PubMedCrossRefGoogle Scholar
  88. 88.
    Senjo M. Obsessive-compulsive disorder in people that abuse codeine. Acta Psychiatr Scand 1989 Jun; 79(6): 619–20PubMedCrossRefGoogle Scholar
  89. 89.
    Amiaz R, Fostick L, Gershon A, et al. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol 2008 Jun; 18(6): 455–61PubMedCrossRefGoogle Scholar
  90. 90.
    Hamidi A, Jahanguiri B, Esfahani MN, et al. Naltrexone in obsessive-compulsive disorder: an open-label trial. Iran J Psychiatry Behav Sci 2007; 1(1): 16–21Google Scholar
  91. 91.
    Sandyk R. Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome. Int J Neurosci 1987 Jul; 35(1-2): 93–4PubMedCrossRefGoogle Scholar
  92. 92.
    Chappell PB, Leckman JF, Riddle MA, et al. Neuroendocrine and behavioral effects of naloxone in Tourette syndrome. Adv Neurol 1992; 58: 253–62PubMedGoogle Scholar
  93. 93.
    Hollander E, Dell'Osso B. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol 2006 May; 21(3): 189–91PubMedCrossRefGoogle Scholar
  94. 94.
    Rubio G, Jimenez-Arriero MA, Martinez-Gras I, et al. The effects of topiramate adjunctive treatment added to anti-depressants in patients with resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2006 Jun; 26(3): 341–4PubMedCrossRefGoogle Scholar
  95. 95.
    Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. Epub 2010 Aug 10Google Scholar
  96. 96.
    Mowla A. Does topiramate adjunction have any effect on obsessions and compulsions in patient with obsessive compulsive disorder? [abstract]. Eur Psychiatry 2010; 25 Suppl. 1: 358CrossRefGoogle Scholar
  97. 97.
    Hewlett WA, Schmid SP, Salomon RM. Pilot trial of ondan-setron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry 2003 Sep; 64(9): 1025–30PubMedCrossRefGoogle Scholar
  98. 98.
    Pallanti S, Bernardi S, Antonini S, et al. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs 2009 Dec 1; 23(12): 1047–55PubMedCrossRefGoogle Scholar
  99. 99.
    Singer HS, Wendlandt J, Krieger M, et al. Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology 2001 Mar 13; 56(5): 599–604PubMedCrossRefGoogle Scholar
  100. 100.
    Albucher RC, Curtis GC. Adderall for obsessive-compulsive disorder. Am J Psychiatry 2001 May; 158(5): 818–9PubMedCrossRefGoogle Scholar
  101. 101.
    Owley T, Owley S, Leventhal B, et al. Case series: adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder. J Child Adolesc Psychopharmacol 2002 Summer; 12(2): 165–71PubMedCrossRefGoogle Scholar
  102. 102.
    Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2009 Nov; 70(11): 1530–5PubMedCrossRefGoogle Scholar
  103. 103.
    Kaplan A, Hollander E. Comorbidity in compulsive hoarding: a case report. CNS Spectr 2004 Jan; 9(1): 71–3PubMedGoogle Scholar
  104. 104.
    Soyka M, Rosner S. Opioid antagonists for pharmacological treatment of alcohol dependence: a critical review. Curr Drug Abuse Rev 2008 Nov; 1(3): 280–91PubMedCrossRefGoogle Scholar
  105. 105.
    Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005 Jun; 8(2): 267–80PubMedCrossRefGoogle Scholar
  106. 106.
    Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry 2008 May; 69(5): 783–9PubMedCrossRefGoogle Scholar
  107. 107.
    Kurlan R, Majumdar L, Deeley C, et al. A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome. Ann Neurol 1991 Jul; 30(1): 19–23PubMedCrossRefGoogle Scholar
  108. 108.
    Mula M, Cavanna AE, Monaco F. Psychopharmacology of topiramate: from epilepsy to bipolar disorder. Neuropsychiatr Dis Treat 2006 Dec; 2(4): 475–88PubMedCrossRefGoogle Scholar
  109. 109.
    Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 2010 May; 71(5): 634–48PubMedCrossRefGoogle Scholar
  110. 110.
    Dannon PN, Lowengrub K, Gonopolski Y, et al. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005 Jan-Feb; 28(1): 6–10PubMedCrossRefGoogle Scholar
  111. 111.
    Arbaizar B, Gomez-Acebo I, Llorca J. Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen Hosp Psychiatry 2008 Sep-Oct; 30(5): 471–5PubMedCrossRefGoogle Scholar
  112. 112.
    Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2010 Jan; 81(1): 70–3PubMedCrossRefGoogle Scholar
  113. 113.
    Ye JH, Ponnudurai R, Schaefer R. Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev 2001 Summer; 7(2): 199–213PubMedCrossRefGoogle Scholar
  114. 114.
    Kenna GA, Zywiak WH, McGeary JE, et al. A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res 2009 Feb; 33(2): 315–23PubMedCrossRefGoogle Scholar
  115. 115.
    Toren P, Weizman A, Ratner S, et al. Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2005 Apr; 66(4): 499–503PubMedCrossRefGoogle Scholar
  116. 116.
    Marshall FH. Is the GABA B heterodimer a good drug target? J Mol Neurosci 2005; 26(2-3): 169–76PubMedCrossRefGoogle Scholar
  117. 117.
    Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007 Dec 8; 370(9603): 1915–22PubMedCrossRefGoogle Scholar
  118. 118.
    Stahl SM. Mechanism of action of stimulants in attention-deficit/hyperactivity disorder. J Clin Psychiatry 2010 Jan; 71(1): 12–3PubMedCrossRefGoogle Scholar
  119. 119.
    Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010 Apr; 19(4): 353–64PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Leonardo F. Fontenelle
    • 1
    • 2
  • Sanne Oostermeijer
    • 1
  • Ben J. Harrison
    • 1
  • Christos Pantelis
    • 1
  • Murat Yücel
    • 1
    • 3
  1. 1.Melbourne Neuropsychiatry Centre, Department of PsychiatryThe University of Melbourne and Melbourne HealthMelbourneAustralia
  2. 2.Anxiety and Depression Research ProgramUniversidade Federal do Rio de JaneiroIpanemaBrazil
  3. 3.Orygen Youth Health Research CentreThe University of MelbourneMelbourneAustralia

Personalised recommendations